Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target

< p > Atopic dermatitis (AD) is   the most common chronic inflammatory skin disease . It affects infancy, but it is also highly prevalent in adults and it is cause of  burden to patients and their families. Nowaday, AD is  recognized as an heterogenous disease, including different subtypes with variable clinical manifestations, in which the impairments of the skin barrier are crucial. The severity of AD dictates the level of treatment. Current AD treatment focuses on restoration of barrier function, mainly through moisturizers and on the control of inflammation by the use of corticosteroids, topical calcineurin inhibitors and immunosuppresive drugs in the most severe cases. However, targeted disease-modifying therapy are under investigations. The most recent findings on the skin microbial dysbiosis is a promising future direction for the development of new treatments. We need to improve the understanding of the comp lex microbiome-host interactions, the role of autoimmunity, the comparative effectiveness of therapies and the ways to implement the educational strategies. < /p > < p >   < /p > < p > DOI   < span > 10.12932/AP0732.34.2. < /span > < span > 2016 < /span > < /p >
Source: Asian Pacific Journal of Allergy and Immunology - Category: Allergy & Immunology Source Type: research